Israeli scientists may have discovered the definitive cure for cancer



[ad_1]

A small team of Israeli scientists believe they might have found the first complete cure for cancer.

"We believe we will offer a complete cure for cancer in one year"Said Dan Aridor, chairman of the board of a new treatment he is developing Accelerated Evolution Biotecnologias Ltda. (AEBi), which was founded in 2000 in the ITEK incubator at Weizmann Science Park. AEBi has developed the Soap, which provides functional clues for very difficult goals.

"Our cancer cure will be effective from the first day, will last a few weeks and will have minimal or no side effects at a much lower cost than most other treatments on the market."Our solution will be generic and personal."

It looks fantastic, especially considering that approximately 18.1 million new cases of cancer are diagnosed worldwide each year, according to reports by the International Agency for Research on Cancer. In addition, every sixth death in the world is due to cancer, which makes it the second leading cause of death (the second is cardiovascular disease).

Aridor and Dr. Ilan Morad, say their treatment, which they call Muto (multiobjective toxin), is essentially on the scale of an antibiotic for cancer, a first order rupture technology. The anti-cancer medicine that can change the game is based on the technology Soap, which belongs to the group of phage display technologies. It involves the introduction of DNA encoding a protein, such as an antibody, into a bacteriophage, a virus that infects bacteria. This protein is then displayed on the surface of the phage. Researchers can use these phages that display proteins to detect interactions with other proteins, DNA sequences and small molecules.

In 2018, a team of scientists won the Nobel Prize for their work on the phase visualization in the directed evolution of new proteins, in particular for the production of antibody therapies.

AEBi is doing something similar, but with peptides, composed of two or more amino acids together in one chain. According to Morad, peptides have several advantages over antibodies, including that they are smaller, cheaper and easier to produce and regulate.

When the company began, Morad said: "We were doing what everyone was doing, trying to discover new peptides specific for specific cancers"But shortly thereafter, Morad and his colleague Dr. Hanan Itzhaki decided they wanted to do something bigger.

To begin, Morad said they had to identify why other drugs and treatments that kill cancer do not work or end up failing. So they found a way to counteract that effect.

To begin, most anti-cancer drugs target a specific target within or on the cancer cellHe explained. Inhibition of the target usually affects a physiological pathway that promotes cancer. Mutations in the targets, or downstream in their physiological pathways, may make the targets not relevant to the nature of the cancer cell, and therefore the drug it attacks becomes ineffective.

In contrast, MuTaTo uses a combination of several cancer-targeted peptides for each cancer cell at the same time, combined with a strong peptidic toxin that would specifically kill the cancer cells. Using at least three peptides targeting the same structure with a strong toxin, Morad said: "We guarantee that the treatment will not be affected by the mutations; the cancer cells can mutate in such a way that the cancer discards the target receptors"

"The probability of having multiple mutations that would modify all target receptors drastically decreases with the number of targets used," continued Morad. "Instead of attacking the receivers one at a time, we attack the receivers three at a time; not even cancer can mutate three receptors at the same time"

In addition, many cancer cells activate detoxification mechanisms when they are under stress due to drugs. The cells pump the medicines or modify them so they do not work. But Morad said that detoxification takes time. When the toxin is strong, it has a high chance of killing the cancer cell before detoxification occurs, which is what he is betting on.

Many cytotoxic anticancer treatments target rapidly growing cells. But cancer stem cells are not growing rapidly and can escape these treatments. So when the treatment ends, they can cause cancer again.

"If you do not completely kill the cancer, the remaining cells may start to mutate again, and then the cancer returns, but this time it is drug resistant, "Morad said.

He explained that because cancer cells are born from mutations that occur in cancer stem cells, most of the overexpressed proteins that target the cancer cell exist in cancer stem cells. MuTaTo's multiple-target attack ensures that it will also be destroyed.

Finally, some cancerous tumors erect shields that create problems of access to large molecules, such as antibodies. MuTaTo acts like an octopus or a piece of spaghetti and can sneak into places where other large molecules can not reach. Morad said the peptide parts of MuTaTo are very small (12 amino acids long) and lack a rigid structure.

"This should cause the entire molecule to not be immunogenic in most cases and would allow repeated administration of the drug."He said.

Morad said his discovery could also reduce side effects unhealthy form of most cancer treatments, which are derived from pharmacological treatments that interact with wrong or additional goals, or the correct goals, but on non-cancerous cells. He said that MuTaTo has a combination of several highly specific peptides for cancer in a framework for each type of cancer cell that would increase the specificity for the cancer cell due to the avidity effect. In addition, in most cases, non-cancerous cells that have a protein in common with cancer cells do not express it in excess.

"This makes a big difference between the two cell types and should drastically reduce the side effects"Morad said.

[ad_2]

Source link